Denny Jacob

4 days ago | wsj.com | Denny Jacob

SpartanNash SPTN 49.62%increase; green up pointing triangle agreed to be acquired by C&S Wholesale Grocers in a deal valued around $1.77 billion, including debt. C&S Wholesale will pay $26.90 a share in cash to acquire the food solutions company. The purchase price represents a nearly 53% premium over SpartanNash’s closing price on Friday of $17.64, and a premium of 42% to its 30-day volume-weighted average stock price as of Friday, according to the companies.

6 days ago | wsj.com | Denny Jacob

Updated June 20, 2025 3:20 pm ETDarden Restaurants DRI 1.36%increase; green up pointing triangle saw sales jump in its latest quarter, boosted in part by promotions aimed at value-seeking customers weary of higher prices for food and groceries. “What we believe is happening right now in the casual-dining space is consumers are figuring out that casual dining is a great value,” said CEO Ricardo Cardenas on an earnings call Friday.

6 days ago | wsj.com | Denny Jacob

Updated June 20, 2025 2:43 pm ETAccenture ACN -6.86%decrease; red down pointing triangle reported a drop in bookings in the latest quarter, prompting investor concern amid a more uncertain relationship with the federal government. The 6% drop in bookings, a closely watched metric that measures future revenue based on contracts, came as the consulting firm on Friday posted higher sales and profit in the third quarter. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.

1 week ago | tradingview.com | Denny Jacob

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract — 3rd UpdateACNAccenture reported a drop in bookings in the latest quarter, prompting investor concern amid a more uncertain relationship with the federal government. The 6% drop in bookings, a closely watched metric that measures future revenue based on contracts, came as the consulting firm on Friday posted higher sales and profit in the third quarter.

1 week ago | tradingview.com | Denny Jacob

AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome TreatmentABBVAbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker said data from the trial doesn't impact any current approved indications for venetoclax. Venetoclax is being developed by AbbVie and Roche.